Description
Retatrutide is a single synthetic peptide engineered to act on three incretin and metabolic receptors at once: GIP, GLP-1 and glucagon.
Research context
It is a subject of current clinical-stage investigation, and laboratories use it to study multi-receptor signalling, receptor selectivity and metabolic pathway models. It is not an approved medicine in Canada.
Retatrutide at a glance
- Compound: single synthetic peptide acting on three receptors
- Targets: GIP, GLP-1 and glucagon receptors
- Research areas: multi-receptor signalling, receptor selectivity, metabolic pathway models
- Supplied as: 10 mg, 20 mg or 30 mg lyophilized powder in a sealed glass vial
Handling and reconstitution
Let the Retatrutide vial reach room temperature before opening to limit condensation. Reconstitute with bacteriostatic water, sterile water or a buffer suited to your assay, adding the diluent slowly down the vial wall and swirling gently rather than shaking. If the powder doesn’t dissolve fully, a dilute acetic acid solution may help where your protocol allows. Aliquot reconstituted Retatrutide to avoid repeated freeze–thaw cycles, and record the lot number with your experimental data.
Specifications
| Amount per vial | 10 mg, 20 mg or 30 mg (choose above) |
|---|---|
| Form | Lyophilized (freeze-dried) powder in a sealed glass vial |
| Storage | Store sealed vials at −20 °C, away from light. Once reconstituted, keep at 2–8 °C. |
| Intended use | In-vitro and laboratory research only |
For laboratory research use only. Not for human or veterinary use, and not a drug, food, cosmetic or supplement. Sold only to qualified researchers who accept our Research Use Policy.
Reviews
There are no reviews yet.